The embodiments disclosed herein relate to a ureteral stent having two stent bodies and a tether. The stent can minimize or prevent migration of the device out of the bladder of the patient while also reducing patient discomfort associated with such stents.

The embodiments disclosed herein relate to a ureteral stent having two stent bodies and a tether. The stent can minimize or prevent migration of the device out of the bladder of the patient while also reducing patient discomfort associated with such stents.

A reversible vasectomy device suitable for reverse vasectomy operations is presented. More specifically, the present invention may take the form of a stent device that installs along the severed vas deferens such that the vas deferens ends are opened and coupled together. The reversible vasectomy device is made out of an absorbable material, allowing the reversible vasectomy device to be absorbed by the body, leaving only the connected vas deferens once the healing process is completed. The reversible vasectomy device contains a first connection element, a second connection element, and a mid-section. The mid-section is connected between the first connection element and the second connection element. The first connection element, the second connection element, and the mid-section are in fluid communication with each other.

A reversible vasectomy device suitable for reverse vasectomy operations is presented. More specifically, the present invention may take the form of a stent device that installs along the severed vas deferens such that the vas deferens ends are opened and coupled together. The reversible vasectomy device is made out of an absorbable material, allowing the reversible vasectomy device to be absorbed by the body, leaving only the connected vas deferens once the healing process is completed. The reversible vasectomy device contains a first connection element, a second connection element, and a mid-section. The mid-section is connected between the first connection element and the second connection element. The first connection element, the second connection element, and the mid-section are in fluid communication with each other.

A method of delivering a pharmaceutical composition to Schlemm’s canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm’s canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm’s canal as it erodes.

A method of delivering a pharmaceutical composition to Schlemm’s canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm’s canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm’s canal as it erodes.

The disclosure relates to a stent assembly for placement of a stent within a ureter. In many embodiments, the stent assembly includes a band coupled to a proximal end of the stent. In many such embodiments, the band may extend into the urethra and facilitate removal of the catheter without the help of a medical professional or requiring a portion of the stent assembly (e.g., suture loop) to extend outside of the patient. In various embodiments, the band may include one or more features that promote patient comfort while the stent is positioned within a body, such as by being atraumatic and/or seamless.

The disclosure relates to a stent assembly for placement of a stent within a ureter. In many embodiments, the stent assembly includes a band coupled to a proximal end of the stent. In many such embodiments, the band may extend into the urethra and facilitate removal of the catheter without the help of a medical professional or requiring a portion of the stent assembly (e.g., suture loop) to extend outside of the patient. In various embodiments, the band may include one or more features that promote patient comfort while the stent is positioned within a body, such as by being atraumatic and/or seamless.

An implantable vein frame is contemplated in which two ring members are rigidly joined in spaced axial alignment via one or more interconnecting members. One of the one or more interconnecting members defines a protruding region that acts upon the implant placed within the frame and/or the vein that the vein frame is placed within to define a sinus region. The implant is placed within and scaffolded by the vein frame, and the vein frame is subsequently inserted within a vein via a venotomy, or interposed between two vein segments via vein interposition graft. The vein frame acts to support the structural integrity of the implant, and to scaffold and anchor the implant in place with the vein.

An implantable vein frame is contemplated in which two ring members are rigidly joined in spaced axial alignment via one or more interconnecting members. One of the one or more interconnecting members defines a protruding region that acts upon the implant placed within the frame and/or the vein that the vein frame is placed within to define a sinus region. The implant is placed within and scaffolded by the vein frame, and the vein frame is subsequently inserted within a vein via a venotomy, or interposed between two vein segments via vein interposition graft. The vein frame acts to support the structural integrity of the implant, and to scaffold and anchor the implant in place with the vein.